

Patent number	Description	Assignee	Inventor	Priority application date	Publication date
WO 2012159023	Assessing the presence or risk of development of encephalopathy in a patient with liver disease by analyzing gut microflora, comparing the microbiome signature, and concluding patient has or is at risk of developing encephalopathy.	Virginia Commonwealth University (Richmond, VA, USA), US Department of Veterans Affairs (Washington, DC), George Mason University (Fairfax, VA, USA)	Bajaj J, Gillevet PM, Sanyal A	5/19/2011	11/22/2012
WO 2012122522	A model gnotobiotic animal comprising a cultured gut microbial community, including a composition comprising an <i>in vitro</i> cultured collection of a gut microbial community or clonally arrayed cultured collection of a gut microbial community, a method for determining the effect of a perturbation on a gut microbial community and a method for predicting variations in abundance of a member of a gut microbiome of a host in response to a proposed diet.	Washington University (St. Louis, MO, USA)	Faith JJ, Goodman A, Gordon JI, Kallstrom G, McNulty NP, Rey FE, Ridaura V	3/9/2011	9/13/2012
WO 2012118535	A biologically active composition isolated from biofilm, a medium in which biofilm is grown or a biological sample extracted from a patient and then grown as biofilm, where the biological activity is the ability to modulate a microbiome to which the composition is administered.	Quorum Innovations (Sarasota, FL, USA)	Berkes EA, Monsul NT	3/1/2011	9/7/2012
WO 2012050513	A method for identifying an individual at risk of developing cardio- vascular disease, involving obtaining an oral sample from the indi- vidual, and determining the presence of specific bacterial groups or species in the oral sample that indicates a risk of developing cardiovascular disease.	Baeckhed F	Baeckhed F	10/11/2010	4/19/2012
WO 2012033814	Inhibiting disease caused by <i>Clostridium</i> in a subject, comprising administering at least one antibiotic to the subject and contacting the environment of the subject with a nontoxigenic strain of <i>Clostridium</i> , where the subject is maintained in the environment for a time sufficient to allow the colonization of the gastrointestinal tract of the subject by the nontoxigenic <i>Clostridium</i> .	ViroPharma (Exton, PA, USA)	Broom C, Tatarowicz WA	9/10/2010	3/15/2012
WO 2012016287	A delivery vehicle, formulation, composition, pharmaceutical preparation, product of manufacture, container or device for prophylactic or therapeutic use, containing an entire or substantially entire microbiota, or complete or partial fecal flora.	Borody TJ	Borody TJ	8/4/2010	2/9/2012
WO 2011107482	A method of diagnosing and treating obesity, involving determining whether at least one gene provided in the patent specification is absent from an individual's gut microbiome.	Institut National de la Recherche Agronomique (Paris), Ehrlich S	Ehrlich S	3/1/2010	9/9/2011
WO 2011107481	A method of diagnosing inflammatory bowel disease, compris- ing determining whether at least one gene provided in the patent specification is absent from an individual's gut microbiome.	Institut National de la Recherche Agronomique (Paris)	Ehrlich S	3/1/2010	9/9/2011
WO 2011094027	Bacteriotherapy for <i>Clostridium difficile</i> colitis, comprising receiving a set of donor fecal samples, receiving a characteristic of each of the set of donor fecal samples, storing a portion of each fecal sample and indexing.	Hlavka EJ, MikrobEX (Minneapolis, MN, USA)	Hlavka EJ	2/1/2010	8/4/2011

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Reuters (Search Service), 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://thomsonreuters.com/).